Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 129, Issue -, Pages 40-43Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2018.06.006
Keywords
Cervical cancer; Immune check-point; Immunotherapy; CTLA-4; PD-1; Ipilimumab; Pembrolizumab; Nivolumab
Categories
Ask authors/readers for more resources
Despite different treatment strategies, locally advanced cervical cancer (CC) persists as one of the most incurable cancers among women worldwide. In fact, this setting of patients are at high risk of persistent and recurrent disease. In recent years, researches have investigated immune check-point inhibitors in hopes of determining improved response to therapy with prolongation of survival. We reviewed the published literature and conference proceedings and presented pivotal trials supporting immune check-point inhibitors use in the treatment of CC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available